Company intelligence / Profile preview

Barcalona

Ownership: Private
Development stage: Commercial

Overview

MedTech Barcelona develops and commercializes innovative cell-based in vitro tools that support ADME-Tox and DMPK studies in drug discovery. Their patented platform enables the shipment of viable cultured cells at room temperature globally, streamlining logistics and supporting immediate use upon arrival. The company is internationally recognized through its ReadyCell brand.

Modalities: DeviceIn vitro toolCell-based assay system
Industry: Non-Drug Biotech

Partnerships

Collaborates with leading organizations, distributors, CROs, pharmaceutical companies, biotechnological companies, academic & research institutions worldwide

Beyond the preview

Go deeper on Barcalona.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Barcalona.

Explore the full profile